Benzene Ring Is Part Of A Substituent Which Contains Oxygen Patents (Class 514/598)
  • Patent number: 9029401
    Abstract: The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Sung Hee Hwang, Aaron T. Wecksler, Christophe Morisseau
  • Publication number: 20150080466
    Abstract: The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Publication number: 20150056213
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 26, 2015
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Publication number: 20140329898
    Abstract: Cosmetic compositions comprising N-substituted sulfonyloxybenzylamines and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The N-substituted sulfonyloxybenzylamines are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventors: Dmitri S. Ptchelintsev, John W. Lyga, Russell J. Wyborski, Qian Zheng, Cheng S. Hwang
  • Publication number: 20140288183
    Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.
    Type: Application
    Filed: June 10, 2014
    Publication date: September 25, 2014
    Inventors: Alan D. Snow, Qubai Hu, Thomas Lake, Judy Cam
  • Patent number: 8686042
    Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: April 1, 2014
    Assignee: Neuropharma, S.A.
    Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
  • Publication number: 20140088156
    Abstract: The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.
    Type: Application
    Filed: February 14, 2012
    Publication date: March 27, 2014
    Applicant: The Regents of the University of California
    Inventors: Bruce D. Hammock, Sung Hee Hwang, Aaron T. Wecksler, Christophe Morisseau
  • Publication number: 20140005240
    Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 2, 2014
    Inventors: Alan D. Snow, Qubai Hu, Thomas Lake, Judy Cam
  • Publication number: 20130261178
    Abstract: A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C3 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; Z is linear C2-3 alkylene; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10 aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or further substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3;
    Type: Application
    Filed: July 5, 2010
    Publication date: October 3, 2013
    Inventors: Shailesh Mistry, Etienne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
  • Publication number: 20130261120
    Abstract: The present invention relates to: *combinations of: component A: one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; and, optionally, component C: one or more further pharmaceutical agents; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; *use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and *a kit comprising such a combination.
    Type: Application
    Filed: September 29, 2011
    Publication date: October 3, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Florian Pühler, Marion Hitchcock
  • Publication number: 20130158067
    Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: December 17, 2012
    Publication date: June 20, 2013
    Applicant: ABBVIE INC.
    Inventor: AbbVie Inc.
  • Patent number: 8466200
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Patent number: 8455687
    Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 4, 2013
    Assignee: ProteoTech, Inc.
    Inventors: Alan D Snow, Qubai Hu, Thomas Lake
  • Publication number: 20130096138
    Abstract: Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Having high inhibitory activity against HIV, the thiourea or urea derivatives can be effectively used in the prophylaxis or therapy of AIDS.
    Type: Application
    Filed: June 17, 2011
    Publication date: April 18, 2013
    Applicant: AVIXGEN INC.
    Inventors: Ji Chang You, Gyoon Hee Han, Chul Ho Lee, Doo Na Song, Koo Hwan Chung
  • Publication number: 20130011417
    Abstract: The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation.
    Type: Application
    Filed: February 18, 2011
    Publication date: January 10, 2013
    Inventors: Duck Jong Han, Sung-eun Yoo, Jeehee Suh
  • Publication number: 20120276121
    Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 1, 2012
    Applicants: INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA, CENIX BIOSCIENCE GMBH
    Inventors: MICHAEL HANNUS, CECILIE MARTIN, MARIA M. MOTA, MIGUEL PRUDENCIO, CHRISTINA DIAS RODRIGUES
  • Publication number: 20120270878
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 2, 2012
    Publication date: October 25, 2012
    Applicant: BAYER HEALTHERCARE LLC
    Inventors: Scott MILLER, Martin OSTERHOUT, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, David E. GUNN, Holia HATOUM-MOKDAD, Marell RODRIGUEZ, Robert SIBLEY, Ming WANG, Tiffany TURNER, Catherine BRENNAN
  • Publication number: 20120245163
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur Gomtsyan, Jerome F. Daanen, Gregory A. Gfesser, Michael E. Kort, Chih-Hung Lee, Heath A. McDonald, Pamela S. Puttfarcken, Eric A. Voight, Philip R. Kym
  • Publication number: 20120214808
    Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Prosidion Limited
    Inventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Simon Andrew Swain, Philippe Wong-Kai-In
  • Patent number: 8227643
    Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: July 24, 2012
    Assignee: ProteoTech, Inc.
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
  • Patent number: 8222451
    Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: July 17, 2012
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
  • Publication number: 20120172396
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: July 5, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK
  • Patent number: 8188288
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: May 29, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Publication number: 20120022103
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt, JR.
  • Publication number: 20110251216
    Abstract: The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g., prostate cancer, breast cancer, other solid tumors, multiple myeloma).
    Type: Application
    Filed: February 10, 2011
    Publication date: October 13, 2011
    Applicant: The Regents of The University of Michigan
    Inventors: Arul M. Chinnaiyan, Sooryanaryana Lnu, Qi Cao
  • Publication number: 20110178088
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 21, 2011
    Applicant: XENTION LIMITED
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20110110958
    Abstract: The invention provides compositions and methods for the treatment of neoplasias that are cytotoxic to neoplastic cells or that modulate JAZ expression, subcellular localization, or biological activity.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 12, 2011
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventors: Jingxin Qiu, Mingli Yang, David A. Ostrov, W. Stratford May
  • Patent number: 7919530
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: April 5, 2011
    Assignee: Proteotech, Inc.
    Inventors: Luke A. Esposito, Joel Cummings, F. Michael Hudson, Alan D. Snow
  • Publication number: 20110071164
    Abstract: This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 24, 2011
    Inventors: Søren Peter OLESEN, Morten Grunnet, Palle Christophersen, Dorte STRØBÆK, Joachim Demnitz, Rie S. Hansen
  • Publication number: 20110071178
    Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.
    Type: Application
    Filed: April 16, 2010
    Publication date: March 24, 2011
    Applicant: Northeastern University
    Inventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
  • Publication number: 20110065760
    Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.
    Type: Application
    Filed: November 23, 2009
    Publication date: March 17, 2011
    Applicant: Jerini AG
    Inventors: Jochen KNOLLE, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
  • Publication number: 20110015195
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: September 23, 2010
    Publication date: January 20, 2011
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Patent number: 7863332
    Abstract: Novel biaromatic compounds having the general formula (I): and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/or of diseases related to the metabolism of lipids) or, alternatively, in cosmetic compositions.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: January 4, 2011
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Jean-Guy Boiteau, Corinne Millois Barbuis
  • Publication number: 20100305152
    Abstract: The shikimate pathway links metabolism of carbohydrates to biosynthesis of aromatic compounds, which is an attractive target for the rational drug and herbicide design because it is essential in algae, higher plants, bacteria, and fungi, but absent from mammals. Thus, the present invention provides a method of inhibiting the growth of bacteria or fungi, especially Helicobacter pylori, through inhibiting enzymes in the shikimate pathway.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 2, 2010
    Applicant: NATIONAL TSING HUA UNIVERSITY
    Inventors: WEN-CHING WANG, WEN-CHI CHENG, JINN-MOON YANG
  • Patent number: 7825162
    Abstract: A method for treating cardiovascular disease, including hyperlipidemia and atherosclerosis, using abietane diterpenoid compound or terpenoid compound isolated from Torreya nucifera as an effective ingredient. The abietane diterpenoid compound or terpenoid compound isolated from Torreya nucifera not only excellently inhibits oxidation of low-density lipoprotein (LDL), but also effectively inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: November 2, 2010
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Tae-Sook Jeong, Woo-Song Lee, Hyoung-Chin Kim, Yang-Kyu Choi, Ju-Ryoung Kim, So-Jin An, Kyoung-Ran Im, Ki-Chang Jang, Og-Sung Moon, Jun-Seock Son
  • Publication number: 20100168108
    Abstract: Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.
    Type: Application
    Filed: January 18, 2010
    Publication date: July 1, 2010
    Applicant: Adolor Corporation
    Inventors: Roland E. Dolle, Karin Worm, Q. Jean Zhou
  • Patent number: 7714170
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A? peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: May 11, 2010
    Assignee: Proteotech, Inc.
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
  • Publication number: 20100063583
    Abstract: Disclosed herein are compositions and methods for treating inflammatory vascular diseases. Examples of inflammatory vascular disease include, but are not limited to, in-stent stenosis, coronary arterial diseases (CAD), angina, acute myocardial infarction, acute coronary syndrome, chronic heart failure (CHF), peripheral arterial occlusive diseases (PAOD), critical limb ischemia (CLI), cardiac, kidney, liver and intestinal ischemia, renal failure, cardiac hypertrophy, atherosclerosis, abdominal aortic aneurysm, vasculitis, carotid artery stenosis.
    Type: Application
    Filed: August 14, 2009
    Publication date: March 11, 2010
    Inventors: Yi-Xin Wang, Le-Ning Zhang, Gabor M. Rubanyi
  • Patent number: 7655696
    Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: February 2, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Patent number: 7612113
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: November 3, 2009
    Assignee: Xention Limited
    Inventors: Takeshi Yura, Muneto Mogi, Klaus Urbahns, Hiroshi Fujishima, Tsutomu Masuda, Toshiya Moriwaki, Nagahiro Yoshida, Toshio Kokubo, Masahiro Shiroo, Masaomi Tajimi, Yasuhiro Tsukimi, Noriyuki Yamamoto
  • Patent number: 7601876
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: October 13, 2009
    Assignee: Proteotech, Inc.
    Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
  • Publication number: 20090239841
    Abstract: Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.
    Type: Application
    Filed: October 24, 2005
    Publication date: September 24, 2009
    Inventors: Alan J. Hutchison, Jun Yuan
  • Publication number: 20090227631
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: November 22, 2006
    Publication date: September 10, 2009
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Publication number: 20090197965
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
    Type: Application
    Filed: November 11, 2008
    Publication date: August 6, 2009
    Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, David S. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, Stephen D. Lorimer
  • Publication number: 20090143374
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A? peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.
    Type: Application
    Filed: December 8, 2008
    Publication date: June 4, 2009
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
  • Publication number: 20090137594
    Abstract: The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.
    Type: Application
    Filed: May 17, 2006
    Publication date: May 28, 2009
    Applicant: Gruenenthal GmgH
    Inventors: Robert Frank, Bernd Sundermann, Hans Schick
  • Publication number: 20090118268
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Publication number: 20090036462
    Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.
    Type: Application
    Filed: July 15, 2005
    Publication date: February 5, 2009
    Applicant: Onconova Therapeutics, Inc.
    Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
  • Publication number: 20090012061
    Abstract: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 8, 2009
    Inventors: Timothy A. Blizzard, Carolyn A. Buser-Doepner, Douglas E. Frantz, Kelly Hamilton, Myle Hoang, Ling Lee, Christopher R. Moyes, Jerry A. Murry, Arash Soheili
  • Publication number: 20080311074
    Abstract: A method of inhibiting NF-?B activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
    Type: Application
    Filed: April 11, 2008
    Publication date: December 18, 2008
    Applicant: INSTITUTE OF MEDICAL MOLECULAR DESIGN INC.
    Inventors: Susumu MUTO, Akiko ITAI